Fast-tracking C010DS-Zn: PARP1-agonist targeting cancer and M2-like macrophages

Logo
Presented by

Jinhyuk Fred Chung, PhD, Chief Scientific Officer, Xylonix Pte. Ltd.

About this talk

Parthanatos (a programmed necrosis from PARP1 hyperactivation) is an untapped death mechanism in oncology, and it offers some ideal features for cancer treatments including immunogenicity and its independence from the drug resistance-ridden p53-apoptosis pathway. Xylonix has developed several synthetic peptide-conjugate APIs including C005D-Zn, C008D-Zn, and C010DS-Zn that were designed to induce parthanatos in cancer, and to varying degrees, M2-like macrophages (M2) with increasing cytotoxicity to both targets in higher-numbered agents. Previously known as the pro-tumor immunity that hampered cancer immunotherapy advances, M2 was also discovered to play the central role in generating both the acute severe cytokine storm and long-term thrombotic complications of COVID19. In the context of the pandemic Xylonix is now focusing to fast-track the C010DS-Zn development with its first target in-human trials against COVID19 with subsequent expansions into oncology and other M2-driven autoimmune diseases. In this talk, I share Xylonix strategy and some breakthrough data for supporting such development goals via aggressive utilization of mechanism studies, genomic information, and large-scale screenings.

Related topics:

More from this channel

Upcoming talks (1)
On-demand talks (37)
Subscribers (2414)
Champions Oncology delivers innovative solutions to oncology drug development, accelerating the journey from the research bench to the clinic – decreasing timelines, lowering costs, and ultimately saving patient lives. Learn more about Champions Oncology's capabilities, our service platforms and educational topics affecting our industry on our Webinar Channel.